Emerging magic bullet: subcellular organelle-targeted cancer therapy
Author:
Yan Yue1, Zhang Yimeng23, Liu Jianxiong23, Chen Binlong12, Wang Yiguang234ORCID
Affiliation:
1. Department of Central Laboratory , Peking University First Hospital , Beijing , China 2. State Key Laboratory of Natural and Biomimetic Drugs , Peking University , Beijing , China 3. Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, School of Pharmaceutical Sciences , Peking University , Beijing , China 4. Chemical Biology Center , Peking University , Beijing , China
Abstract
Abstract
The therapeutic efficacy of anticancer drugs heavily relies on their concentration and retention at the corresponding target site. Hence, merely increasing the cellular concentration of drugs is insufficient to achieve satisfactory therapeutic outcomes, especially for the drugs that target specific intracellular sites. This necessitates the implementation of more precise targeting strategies to overcome the limitations posed by diffusion distribution and nonspecific interactions within cells. Consequently, subcellular organelle-targeted cancer therapy, characterized by its exceptional precision, have emerged as a promising approach to eradicate cancer cells through the specific disruption of subcellular organelles. Owing to several advantages including minimized dosage and side effect, optimized efficacy, and reversal of multidrug resistance, subcellular organelle-targeted therapies have garnered significant research interest in recent years. In this review, we comprehensively summarize the distribution of drug targets, targeted delivery strategies at various levels, and sophisticated strategies for targeting specific subcellular organelles. Additionally, we highlight the significance of subcellular targeting in cancer therapy and present essential considerations for its clinical translation.
Funder
National Natural Science Foundation of China National Key Research and Development Program of China
Publisher
Walter de Gruyter GmbH
Reference176 articles.
1. Fane, M, Weeraratna, AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer 2020;20:89–106. https://doi.org/10.1038/s41568-019-0222-9. 2. Chen, H, Zhang, W, Zhu, G, Xie, J, Chen, X. Rethinking cancer nanotheranostics. Nat Rev Mater 2017;2:17024. https://doi.org/10.1038/natrevmats.2017.24. 3. Wang, S, Liu, Y, Feng, Y, Zhang, J, Swinnen, J, Li, Y, et al.. A review on curability of cancers: more efforts for novel therapeutic options are needed. Cancers 2019;11:1782. https://doi.org/10.3390/cancers11111782. 4. Alibakhshi, A, Kahaki, FA, Ahangarzadeh, S, Yaghoobi, H, Yarian, F, Arezumand, R, et al.. Targeted cancer therapy through antibody fragments-decorated nanomedicines. J Contr Release 2017;268:323–34. https://doi.org/10.1016/j.jconrel.2017.10.036. 5. Wang, L, Qin, W, Huo, YJ, Li, X, Shi, Q, Rasko, JEJ, et al.. Advances in targeted therapy for malignant lymphoma. Signal Transduct Target Ther 2020;5:15. https://doi.org/10.1038/s41392-020-0113-2.
|
|